En español
NIDA

Pioneering early stage researchers selected for NIDA’s 2016 Avenir awards

Awards recognize cutting edge HIV/AIDS and epigenetics research

June 09, 2016

Red ribbon to represent HIV/AIDResearch and a DNA molecule to represent Genetics or Epigenetics research

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, today announced seven recipients of its two Avenir Award programs for HIV/AIDS and genetics or epigenetics research. The awards will support exciting approaches with tools such as genome editing and smart phone technologies, as well as studies of epigenetic changes in brain cells and couples-based HIV prevention. The Avenir (the French word for “future”) Awards provide grants to early stage investigators who propose highly innovative studies. Each of the seven scientists will receive up to $300,000 per year for five years to support their projects.

The five HIV/AIDS projects receiving awards propose to explore a wide range of approaches, including: using a novel immunization strategy to develop a HIV vaccine for individuals with substance use disorder; utilizing a new genome editing technique to identify genes required for HIV latency to support development of therapeutic targets; evaluating the cost-effectiveness of strategies aimed at improving awareness of HIV status and subsequent linkages to care; testing the effectiveness of smart-phone mobile health technology to collect patient information that may aid in HIV treatment adherence; and developing and evaluating a couples-based HIV prevention program for young substance-using males. The genetics and epigenetics research awardees are focused on two areas: identifying novel roles for the neurotransmitter dopamine in the regulation of patterns of neuronal gene expression to allow for development of more effective therapeutics; and examining epigenetic changes that occur in different types of brain cells to understand the interaction between cannabis abuse and other psychiatric disorders.

"NIDA is very pleased to support these pioneering approaches to advancing addiction science in the areas of epigenetics and HIV/AIDS," said NIDA Director Nora D. Volkow, M.D. "It’s extremely gratifying to be able to support investigators in the early stages of their scientific careers."

The Avenir Award Program for Research on Substance Abuse and HIV/AIDS supports scientists interested in pursuing pioneering research approaches for improved prevention and treatment, long term retention in care, and ultimately, eradication of HIV within substance using populations infected with, or at risk for, HIV/AIDS. The Avenir Award Program for Genetics or Epigenetics of Substance Abuse supports early stage investigators engaged in promising research in the field of genetics or epigenetics of substance abuse. Epigenetics studies how environmental factors influence changes in gene expression without altering the DNA sequence.

Awardees are listed below:

HIV/AIDS Research

Daniel Lingwood, Ph.D., Massachusetts General Hospital, Boston
Project: Defining and Exploiting a Genetic Template for an HIV Vaccine

Alexander Marson, Ph.D., University of California, San Francisco
Project: Functional Testing of Host Genes That Control HIV Latency in Primary Immune Cells

Michael Newcomb, Ph.D., Northwestern University, Evanston, Illinois
Project: A New Approach to Integrating Primary and Secondary HIV Prevention in Young Male Couples

Sunil Solomon, Ph.D., Johns Hopkins University, Baltimore
Project: Reaching the Hardest of the Hard-to-Reach

Ryan Westergaard, Ph.D., University of Wisconsin-Madison
Project: Optimizing HIV Care for Patients with Substance Use Disorders using Predictive Analytics in a Mobile Health Application

Genetics or Epigenetics Research

Ian Maze, Ph.D., Icahn School of Medicine at Mount Sinai, New York City
Project: Roles for Histone Monoaminylation in Cocaine-Induced Transcriptional and Behavioral Plasticity

Francesca Telese, Ph.D., University of California, San Diego
Project: Epigenomic Approaches to Study the Gene Networks Underlying the Cannabis Effect on Genetic Vulnerability to Psychosis

Read more about the Avenir Award Program. For information about NIDA’s AIDS Research Program, go to www.drugabuse.gov/AIDS.  Read more about NIDA’s Genetics and Molecular Neurobiology Research Branch.

Lingwood, Marson, Newcomb, Solomon, Westergaard, Maze, and Telese are funded under grant numbers DA042422, DA042423-01, DA042417, DA040244-01, DA042424-01, DA042078-01, and DA042232-01, respectively.

Contact:
NIDA Press Office
301-443-6245
media@nida.nih.gov

About the National Institute on Drug Abuse (NIDA): The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at drugpubs.drugabuse.gov. NIDA’s media guide can be found at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH. . .Turning Discovery Into Health®

News Releases

Mar 2017

Feb 2017

Dec 2016

Nov 2016

Oct 2016

Sep 2016

Aug 2016

Jul 2016

Jun 2016

May 2016

Apr 2016

Mar 2016

Feb 2016

Jan 2016

Dec 2015

Nov 2015

Oct 2015

Sep 2015

Aug 2015

Jul 2015

Jun 2015

May 2015

Apr 2015

Mar 2015

Feb 2015

Jan 2015

Dec 2014

Nov 2014

Oct 2014

Sep 2014

Aug 2014

Jul 2014

Jun 2014

May 2014

Apr 2014

Mar 2014

Feb 2014

Jan 2014

Dec 2013

Nov 2013

Oct 2013

Sep 2013

Aug 2013

Jul 2013

Jun 2013

May 2013

Apr 2013

Mar 2013

Feb 2013

Jan 2013

Dec 2012

Nov 2012

Oct 2012

Sep 2012

Aug 2012

Jul 2012

Jun 2012

May 2012

Apr 2012

Mar 2012

Feb 2012

Jan 2012

Dec 2011

Nov 2011

Oct 2011

Sep 2011

Aug 2011

Jul 2011

Jun 2011

May 2011

Apr 2011

Mar 2011

Jan 2011

Dec 2010

Nov 2010

Sep 2010

Aug 2010

Jul 2010

May 2010

Apr 2010

Mar 2010

Jan 2010

Get this Publication

Cite this article

APA style citation

NIDA (). Pioneering early stage researchers selected for NIDA’s 2016 Avenir awards. Retrieved , from https://www.drugabuse.gov/news-events/news-releases/2016/06/pioneering-early-stage-researchers-selected-nidas-2016-avenir-awards

press ctrl+c to copy
Receive Latest Science Articles in your Email!
You will only receive messages related to Latest Science